Iterum Therapeutics plc (ITRMF) Retained Earnings (2017 - 2025)

Iterum Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$506.5 million in Q3 2025.

• On a quarterly basis, Retained Earnings fell 5.62% year-over-year to -$506.5 million in Q3 2025; TTM through Sep 2025 was -$506.5 million, a 5.62% decrease from a year earlier, with the FY2024 full-year figure at -$486.1 million, down 5.37% from the prior year.
• Retained Earnings was -$506.5 million for Q3 2025 at Iterum Therapeutics, down from -$497.5 million in the prior quarter.
• The five-year high for Retained Earnings was -$374.3 million in Q3 2021, with the low at -$506.5 million in Q3 2025.
• Average Retained Earnings over 5 years is -$437.8 million, with a median of -$445.1 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Retained Earnings plunged 53.71% in 2021, then climbed 1.0% in 2022.
• Over 5 years, Retained Earnings stood at -$378.5 million in 2021, then fell by 11.74% to -$422.9 million in 2022, then retreated by 9.07% to -$461.3 million in 2023, then decreased by 5.37% to -$486.1 million in 2024, then decreased by 4.19% to -$506.5 million in 2025.
• The last three Retained Earnings figures came in at -$506.5 million (Q3 2025), -$497.5 million (Q2 2025), and -$491.0 million (Q1 2025), per Business Quant data.